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ABSTRACT 
 
Background 
Dementia is a growing public health concern as the population ages. Vascular 
dementia is the second most common type of dementia behind Alzheimer’s, and is caused 
by cerebrovascular damage, such as infarcts and hemorrhages. As in systemic 
cardiovascular disease, diabetes and hypertension are leading risk factors for 
cerebrovascular pathology. Anti-hypertensive treatment (AHT), therefore, may have a 
role in preventing cerebrovascular damage. 
Methods 
A case-control study design was utilized to evaluate any association between 
AHT during life and cerebrovascular pathology in autopsy in diabetic participants from 
the National Alzheimer’s Coordinating Centers (NACC). Pathology outcomes included 
infarcts of various sizes and arteriolosclerosis. Exposure was classified as any reported 
use, use at last visit, and percentage of visits with reported use. Adjusted logistic 
regression was used to compare cases and controls. 
Results 
 Among 484 study participants, 74-90% reported exposure to AHT. Among 
exposed participants, CVD (54% vs 23%) and hypercholesterolemia (76% vs 61%) were 
more common. In unadjusted logistic analyses, any infarct and large infarct cases were 
associated with 1.64 and 2.22 times greater odds of exposure reported at last visit than 
controls. In multiple adjusted analyses, only cases with large infarct pathology were 
associated with greater odds of exposure reported at last visit [OR, 95% CI = 2.59 (1.02-
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6.59)]. Large infarcts were also associated with increasing percentage of visits with 
reported AHT.  
Conclusions 
 Large infarct pathology was associated with exposure to AHT at last visit and 
with increased percentage visits with reported AHT. Though not significant for all 
pathology or exposure definitions, consistent direction and magnitude of effects were 
seen, suggesting that cerebrovascular pathology may be associated with AHT exposure. 
Most notably, the odds of exposure to AHT for participants with large infarcts were 
consistently more than double the odds for controls, regardless of exposure definition or 
adjustment.  
 Based on pathophysiology of cardiovascular and cerebrovascular disease, an 
association between pathology and AHT is surprising and questionable. Despite 
adjustment for confounders, residual confounding is likely present. This result highlights 
the complicated time course cerebrovascular pathology and the importance of accurate 
measurement of risk factors and exposure during life.  
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LITERATURE REVIEW 
 
As the population ages, dementia is quickly becoming a major public health 
concern. Estimates of the prevalence of worldwide dementia range from 27 to 36 
million,1 and annual worldwide costs are estimated to be greater than 600 billion dollars 
as of 2010.2 The proportion of the world’s population that is over 65 years of age is 
projected to more than double by 2030.3 Dementia is primarily a syndrome of the elderly, 
and all forms of dementia are presently incurable. The risks for Alzheimer’s Disease 
(AD) and vascular dementia (VaD), which are the most common forms of dementia, 
increase with age, doubling every 4.5 and 5.3 years, respectively.4 Therefore, the burden 
of dementia is expected to greatly increase, demanding focused public health 
intervention.  
Vascular dementia is primarily due to small vessel disease in the brain and is 
estimated to account for approximately 15% of clinically diagnosed AD cases, and 15-
20% of all dementia cases, making it the second leading cause of dementia behind 
Alzheimer’s.3,4 VaD appears to be caused by arteriosclerosis and atherosclerosis of blood 
vessels in the brain. Brain arteriosclerosis has been associated with decreased cognitive 
scores and hypertension.5 In addition to arteriosclerosis and atherosclerosis, specific brain 
pathology findings of VaD include both large and small infarcts, which can confirm 
diagnosis at autopsy.  
While the exact association between VaD and AD is still unclear, they are not 
mutually exclusive as several risk factors and pathologic changes in the brain overlap 
both disorders.3,6 Mixed dementias (e.g., dementia in the presence of multiple 
pathologies, such as AD and cerebrovascular disease) become more common with age, 
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further complicating diagnosis, classification, and treatment.4 In fact, VaD is often 
diagnosed as AD and treated with the same medications as AD (acetylcholinesterase 
inhibitors and NMDA antagonists), despite lack of evidence of benefit.4 
Diabetes and Dementia 
 
Diabetes is an enormous public health concern. Between 1980 and 2014, the 
number of new diabetes diagnoses tripled,9 and the annual total cost in 2012 was 
estimated to be $245 billion.10 Diabetes is a well-established risk factor for 
cardiovascular disease and often accompanied by comorbid hypertension. This would 
suggest that diabetes might also be contributory to VaD and other dementias. However, 
with studies finding mixed results, the association between diabetes and dementia 
remains complex and controversial. 
Historically, diabetes has been considered a risk factor for dementia, and a recent 
meta-analysis found diabetes to be associated with greater mortality in dementia.11 
Diabetes has consistently been associated with cognitive decline, and several studies have 
shown diabetes to be associated with higher risk for AD and VaD, infarcts, brain atrophy, 
and cellular death in the brain, inflammation, and increased amyloid plaques.12, 13 There 
has long been discussion of AD as a potential “type 3 diabetes” due to similarities in 
insulin resistance and oxidative damage mechanisms.14 In mouse models, AD pathology 
has been associated with and induced by diabetes, but human studies with autopsy 
verified measures have not found an association between diabetes and Alzheimer’s 
pathology.12  
For example, an investigation by Sonnen et al. found dementia in diabetics to be 
associated with vascular pathology more than AD pathology, while dementia in non-
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diabetics was associated with more AD pathology. Diabetes was also associated with 
greater severity of cerebral atherosclerosis.15 The prospective Vantaa 85+ study found 
similar results among the “oldest old” (i.e. >85 years). Incidence of dementia for 
diabetics was twice that of nondiabetics, mortality was 30% higher, and diabetics were 
more likely to have cerebrovascular pathology and less likely to have Alzheimer’s 
pathology.16 In a large neuropathologic study of >2300 participants, diabetics were 
estimated to have 54-57% greater odds of having any infarct compared to participants 
without diabetes. No association was found between AD and diabetes for multiple 
measures of AD pathology.17 These results were recently confirmed by Pruzin et al. and 
support the association between diabetes, cerebrovascular disease, and dementia.18 
Hypertension and Dementia 
 
In the United States, nearly one-third of adults over 18 years of age have been 
diagnosed with hypertension, and the prevalence of hypertension increases to nearly two-
thirds for adults age 60 and older. Over 80% of adult cases over the age of 60 are treated 
with medications, while about one-half are controlled (blood pressure less than 140/90).7 
Mid-life hypertension is an established risk factor for dementia and cognitive decline, but 
the relationship is complex and difficult to fully elucidate given the progressive and long-
term nature of hypertension, cardiovascular disease, and dementia.6  
Hypertension is contributory to both cerebrovascular and cardiovascular diseases, 
which have been associated with both cerebrovascular and AD pathology.4 Specifically, 
hypertension has been associated with pathologic changes in small blood vessels in the 
brain, including atrophy, microbleeds, and lacunar infarcts. To complicate matters 
further, AD has also been associated with cerebrovascular disease, and the apolipoprotein 
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E (APOE) ε4 allele, an established risk factor for AD, has been associated with 
cardiovascular disease as well.6  
Given the interconnectedness of dementia and cardiovascular disease, increasing 
interest is being focused on early prevention and the role for antihypertensive therapy 
(AHT). Recent findings from the Framingham Heart Study suggest that observed 
decreases in incidence of dementia in study participants over the past three decades may 
be associated with improved cardiovascular health and large increases in the use of 
AHT.8  
Antihypertensive Treatment 
 
Based on the known and suspected pathophysiology of dementia, many studies 
have investigated the role for AHT in preventing or decreasing progression of dementia. 
AHTs, including angiotensin converting enzyme inhibitors (ACEIs), calcium channel 
blockers (CCBs), ß-blockers, and angiotensin receptor blockers (ARBs), have been 
shown to decrease or slow cognitive decline in some observational studies, while AHT 
has shown mixed results in randomized trials.6,19,20 In addition, some meta-analyses have 
shown decreased risk of VaD but not AD with AHT.19 Significant differences in study 
samples and methods likely contribute to variation in study results. 
Most studies have focused on outcomes of cognitive decline or incident dementia 
and are limited by relatively short follow up times and lack of neuropathology. The long 
time course of the development of dementia makes for difficult, lengthy, and expensive 
follow up. Mid-life blood pressure measurements and full knowledge of lifetime 
exposure to AHT would be ideal but nearly impossible for most studies.  
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Hajjar et al. investigated the association between ARBs and AD neuropathology 
at autopsy21 in participants from the National Alzheimer’s Coordinating Center (NACC) 
database.22 Their cross-sectional analysis found that ARB treatment was associated with 
fewer amyloid plaques when compared to other AHT medications and compared to no 
treatment.21 ARB treatment was also associated with large artery infarcts and 
hemorrhage. However, confounding by indication likely explains this, as patients treated 
with ARBs were more likely to report a history of stroke. 
In a longitudinal study of NACC participants without dementia at baseline, Qiu et 
al. found ACEIs to be inversely associated with diagnosis of dementia (OR: 0.32-68, 
depending on model) in participants without the APOE ε4 allele but no association in 
participants with the allele, suggesting that APOE ε4 positive clinical AD is less 
associated with vascular risks than APOE ε4 negative AD.23 A limitation of the study is 
the lack of autopsy to confirm clinical diagnosis, since clinical and neuropathological 
diagnoses are often discordant.24 
AHT has also been associated with slowing progression from mild cognitive 
impairment (MCI) to AD. Wharton et al. showed an association between the use of renin-
angiotensin system modifying drugs (ACEIs and ARBs) and lower conversion rates from 
MCI to AD.25 The study did not report results for treatment with other medications, and 
vascular pathology was not investigated. Finally, another study found that AHT with 
CCB was associated with delayed progression in cognitive impairment regardless of 
APOE ε4 allele status.4 
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Hypothesis 
 
Diabetes and hypertension are well-established risk factors for cardiovascular and 
cerebrovascular disease, which would suggest a logical association with cerebrovascular 
pathology typical of vascular cognitive impairment and dementia. Furthermore, 
observational studies support such an association. The current body of literature shows 
mixed results regarding the impact of AHT in preventing and slowing development of 
dementia, but few studies have specifically considered vascular dementia or had the 
benefit of autopsy confirmation of diagnosis. The novelty of this study is that it 
investigates the association of AHT with cerebrovascular pathology in a high-risk 
population of participants with comorbid diabetes. The study hypothesis is that AHT will 
be associated with less cerebrovascular pathology in our sample of diabetics.    
METHODS 
 
Sample 
 
The source of data was the National Alzheimer’s Coordinating Center (NACC) 
combined Uniform Data Set (UDS) and Neuropathology Data Set (NP), which compile 
standardized, longitudinal data on enrolled participants from 34 past and present 
Alzheimer’s Disease Centers (ADCs) across the United States. NACC data have been 
described previously and are freely available to researchers at 
https://www.alz.washington.edu/WEB/researcher_home.html. Because the NACC data 
are de-identified, no Institutional Review Board (IRB) approval was required for the 
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current study. However, all ADC studies were covered by IRBs at their home institutions, 
and all participants provided written informed consent. 
Participants were included in the study if diabetes was indicated during follow-up 
and an autopsy was performed upon death. Diabetes was defined as self-reported history 
of diabetes or use of any diabetes medication, including insulins, sulfonylureas, 
biguanides, oligosaccharides, thiazolidinediones, meglitinides, dipeptidyl-peptidase-IV 
(DPP-IV) inhibitors, amylin analogues, and incretin mimetics. Participants were excluded 
if information regarding exposure to anti-hypertensive medication was unavailable.  
Study Design 
 
Association between exposure to anti-hypertensive therapy and cerebrovascular 
pathology was investigated using multiple case-control analyses. Cases were defined by 
presence of cerebrovascular pathology, including large infarcts (at least 1cm in largest 
diameter), lacunes (small arterial infarcts or hemorrhages less than 1cm in diameter), 
microinfarcts (detected microscopically), and amount of arteriolosclerosis (none, mild, 
moderate, severe). Exposure was considered separately as any reported use of AHT, AHT 
reported at last visit, and percentage of total visits with reported use of AHT. 
Variables 
 
Continuous variables of interest included age at death, years of education, body 
mass index (BMI), year of death, and years of smoking. Categorical variables of interest 
included sex, race (white, black, other), Hispanic ethnicity (yes/no), living situation 
(alone or with others), residence (private residence; retirement community or independent 
group living; assisted living, adult family home, or boarding home; skilled nursing 
facility, nursing home, hospital, or hospice); ADC; history of alcohol abuse (yes/no); 
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established diagnosis of dementia (yes/no); and current diabetes medication (yes/no). Past 
medical history of the following comorbidities was considered positive if self-reported as 
either present/active or remote/inactive: hypertension, stroke (combined transient 
ischemic attack or stroke), atrial fibrillation, heart attack, congestive heart failure, and 
hypercholesterolemia. Any history of stroke, atrial fibrillation, heart attack, or congestive 
heart failure was considered positive for a history of “cardiovascular disease.” Presence 
of significant Alzheimer’s pathology was also considered and defined as Braak stage 
V/VI plus moderate to severe CERAD plaque rating.26  
Statistical Methods 
 
All statistical analyses were performed using SAS 9.4 (SAS Institute, Inc.; Cary, 
NC, USA). Descriptive statistics are reported for all variables and outcomes, including 
frequencies and percentages for categorical variables and mean and standard deviation 
for continuous variables. Between group comparisons based on any AHT exposure were 
made using t-tests for continuous variables and chi-square or Fisher’s exact tests for 
categorical variables.  
Unadjusted logistic regression was performed to evaluate any association between 
exposure to AHT (any AHT, AHT at last visit, and percentage of visits with reported 
AHT) and cerebrovascular pathology (any infarct, large infarct, lacunar infarct, 
microinfarct, arteriolosclerosis) with absence of that pathology being the reference 
category.  
Variables were considered as potential confounders based on literature review and 
known pathophysiology.5, 13, 27 DAGitty software28 was utilized to create a directed 
acyclic diagram (DAG) of the hypothetical relationships of variables (Figure 1) and to 
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determine the following minimum sufficient adjustment sets to evaluate the association 
between exposure to AHT and cerebrovascular disease pathology: (1) history of 
hypertension, history of cardiovascular diseases; (2) history of hypertension, history of 
cardiovascular diseases, age at death, history of hypercholesterolemia, genetics/family 
history. Considering CVD as composite variable versus individual cardiovascular disease 
components (i.e. stroke, myocardial infarction, atrial fibrillation, congestive heart 
disease) did not significantly change results. Therefore, the composite CVD variable was 
used for final models. Model 1 adjusted for past medical history of hypertension and past 
medical history of cardiovascular diseases, while Model 2 also included age at death and 
hypercholesterolemia. Genetics/family history was excluded from model 2 due to lack of 
available data.  
Using a case-control design, adjusted odds ratios with 95% confidence ratios were 
calculated for the relationship between each cerebrovascular pathology of interest and 
exposure to AHT, including any exposure, exposure at last visit, and percentage of visits 
with reported exposure. 
RESULTS 
 
Descriptive Statistics 
 
From the entire NACC UDS of 32,938 participants, 3,920 (59% of deaths) 
completed autopsy and 501 autopsied participants were considered diabetics. Of those, 17 
participants were excluded for missing data regarding exposure to AHT bringing the total 
sample size to 484. This sample size varied among analyses based on missing pathology 
data for each outcome. Figure 2 shows participant inclusion and exclusion. 
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Study participants were mostly well educated, elderly, white, male, non-smokers 
living with others. Any exposure to AHT was reported in 81.4% (394/484) of 
participants, while AHT during last visit was present in 74% (352/475) of participants. 
On average, exposed participants reported AHT use during 89.7% of visits. The most 
frequent anti-hypertensive medication classes reported at last visit were: ß-blockers 
(34.9%), ACE inhibitors (28.1%), diuretics (27.9%), calcium channel blockers (19.6%), 
anti-adrenergics (15.9%), angiotensin II blockers (13.2%), and vasodilators (5.4%).  
Comparing exposure groups, those with any exposure to AHT were slightly older 
(80.1 vs 75.5 years, p=0.0005), died about one calendar year later on average (2011.2 vs 
2010.4, p=0.0061), and had about one more visit on average than unexposed participants 
(3.5 vs 2.3, p<0.0001). Composite cardiovascular disease (54.1 vs 23.1, p<0.0001) and 
individual disease components were more common in those exposed to AHT. 
Hypercholesterolemia (76.2% vs 60.7%, p=0.0028) and length of smoking (13.1 vs 9.2 
years, p=0.0349) were also greater in the exposed group. Diagnosis of dementia and 
Alzheimer’s pathology were both less common among those with AHT exposure (37.3 vs 
51.1%, p=0.05). Full descriptive and bivariate statistics can be found in Tables 1 and 2. 
Non-significant differences in cerebrovascular pathology were observed between 
exposure groups. Presence of any infarct and large infarcts were more common in 
exposed participants, while presence of lacunes, microinfarcts, and arteriolosclerosis 
were similar. Table 3 shows full results for distribution of cerebrovascular pathology. 
Unadjusted Logistic Regression 
 
Unadjusted logistic regression showed consistent direction and magnitude of 
association between AHT exposure and cerebrovascular pathology (Table 4). The 
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presence of any size infarct was associated with 1.64 to 1.72 times greater odds of AHT 
exposure for different measures of exposure, though the increase was not significant for 
“any AHT.” The odds of AHT exposure were 2.18 to 2.56 times greater when large 
infarcts were present compared to lack of large infarcts, though the increase was again 
nonsignificant for “any AHT.” Likewise, a nonsignificant increase in odds of AHT 
exposure was seen when lacunes and microinfarcts were present (OR: 1.39-1.51 and 
1.05-1.13, respectively). Mild and moderate arteriolosclerosis were also associated with 
nonsignificantly increased odds of AHT exposure ranging from 18% to 44% for mild and 
49% to 59% for moderate. Severe arteriolosclerosis was not associated with any 
consistent or significant change in odds of AHT exposure. 
Adjusted Logistic Regression 
 
Any AHT 
Neither Model 1 nor Model 2 found any statistically significant association 
between any cerebrovascular pathology and any known exposure to AHT, though odds of 
exposure were greater when any size infarcts, large infarcts, mild arteriosclerosis, and 
moderate arteriolosclerosis were present versus absent. Odds of exposure were 5-35% 
greater when an infarct of any size was present compared to absence of any infarct. That 
increase was driven by large infarcts with 2-2.6 times the odds of exposure compared to 
when large infarcts were absent. 
Odds of exposure were 18-24% greater when mild arteriolosclerosis was present 
versus absent, and odds of exposure were 32-43% greater when moderate 
arteriolosclerosis was present versus absent. For severe arteriolosclerosis, odds of 
exposure were lower (OR: 0.61-0.66).  
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AHT at Last Visit 
Similar results were observed when considering exposure as reported AHT at last 
visit. Odds of exposure were 19-37% greater when infarcts of any size were present 
versus absent and 18-37% greater when lacunes were present versus absent, though no 
statistically significant associations were found. The presence of large infarcts, however, 
was associated with significantly greater odds of exposure in model 1 (OR, 95% CI: 2.59, 
1.02-6.58). Model 2 found a much lower and non-significant increase in odds of exposure 
when large infarcts were present (OR, 95% CI: 2.11, 0.83-5.39). 
Odds of exposure were 43-46% and 31-34% greater when mild and moderate 
arteriolosclerosis was present versus absent, respectively. For severe arteriolosclerosis, 
odds of exposure were again lower (OR: 0.83-0.85). 
Percentage of Visits with AHT 
Similar results were again observed when considering exposure as a percentage of 
total visits with reported AHT. For each unit increase in percentage of visits with 
reported AHT, odds of pathology increased 18-39% for infarcts of any size and 2-19% 
for microinfarcts, though no statistically significant associations were found. However, 
model 1 found that odds of large infarct pathology increased over 300% for each unit 
increase in percentage of visits with reported AHT (OR, 95% CI: 3.15, 1.13-8.78). Model 
2 found a lower increase in odds of large infarct pathology (OR, 95% CI: 2.72, 0.95-
7.76). 
Odds of arteriosclerosis increased by 10-13% for mild and 26-33% for moderate 
pathology for a unit increase in percentage of visits with reported AHT, while odds of 
severe arteriolosclerosis decreased (OR: 0.64-0.68). 
Cerebrovascular pathology and AHT 
 17 
DISCUSSION 
 
In this study sample of elderly diabetic patients, presence of large cerebrovascular 
infarcts in autopsy was associated with exposure to AHT reported at last visit in one of 
two models. In addition, odds of large infarct pathology increased with increasing 
percentage of total visits reporting AHT. 
Across multiple definitions of exposure to AHT, consistent direction and 
magnitude of effects were seen, suggesting that cerebrovascular pathology may be 
associated with AHT exposure. Most notably, the odds of exposure to AHT for 
participants with large infarcts were consistently more than double the odds for controls, 
regardless of exposure definition or adjustment. This larger effect on large infarcts is 
consistent with past studies of cerebrovascular pathology that have shown more 
variability in visible infarcts (i.e. large infarcts and lacunes) compared to 
microinfarcts.17,18,21 
Given the protective effect of blood pressure control in cardiovascular and 
cerebrovascular disease, these results should be questioned. Participants exposed to AHT 
tended to have more comorbidities for which AHT would be indicated, including stroke, 
hypertension, heart attack, congestive heart failure, and atrial fibrillation. In addition, 
hypercholesterolemia was more frequent among exposed participants. Cardiovascular 
diseases and hypercholesterolemia are known risk factors for vascular pathology in the 
brain and systemically, including vessel stenosis, atherosclerosis, and infarcts. These 
covariates were included in adjusted models, but residual confounding cannot be ruled 
out. 
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The pathophysiological time course must also be taken into consideration. Midlife 
blood pressure values and lifelong AHT exposure were not known for the study sample. 
Even participants with multiple visits would have had information limited to the last few 
years of life, which may not accurately reflect long term cerebrovascular damage or AHT 
exposure. It is likely that participants exposed to AHT accumulated cerebrovascular 
damage due to the comorbidities requiring AHT. In that case, significant damage may 
have already been done regardless of late life AHT.  
The same concern exists for diabetes control. In the study sample of diabetics, 
only 65.9% reported pharmacologic treatment for diabetes at last visit. Likewise, 
treatment with an ACE inhibitor or ARB is standard of care for diabetic patients with 
renal or cardiovascular disease (including HTN)29, but only 28.1% and 13.2% of 
participants, respectively, reported use of those medications at last visit. While deviations 
from standards of care may be warranted in some cases, especially during end-of-life 
care, early and sustained intervention is vital to prevention of cardio- and cerebrovascular 
diseases. 
It is unlikely that AHT, known to decrease risk of cardiovascular disease, is truly 
associated with increased cerebrovascular pathology. Given the likely confounding by 
indication described above, it is possible that the AHT was even somewhat protective 
against cerebrovascular pathology. Consider the following: those exposed to AHT should 
be at higher risk of cerebrovascular damage due to underlying disease. If long term 
damage and/or residual confounding existed, one would expect exposed participants to 
have more resulting damage. While a consistent trend in that direction was found, 
perhaps a stronger or more widespread association might have been seen if those 
Cerebrovascular pathology and AHT 
 19 
participants had not been exposed to AHT and experienced the full course of their 
underlying diseases. Thus, the results of this study would fall between the hypothetical 
results of: (1) a fully controlled comparison of exposed participants (who are adequately 
treated for underlying disease) and unexposed (i.e. untreated) participants, and (2) the 
results of a comparison between people with untreated cardiovascular disease and 
disease-free controls. In the first scenario, AHT should be protective, and in the second, 
cerebrovascular pathology should be much more common in the group with CVD. 
Without adequate control for CVD and HTN in the present study, the results should fall 
in the middle of the hypothetical studies. 
To my knowledge, this is the first study of its kind. Other studies have considered 
AD pathology and AHT as well as diabetes and cerebrovascular pathology but not an 
association of AHT with cerebrovascular pathology (AD or vascular) specifically in 
diabetics. Diabetes has consistently been shown to be associated with cerebrovascular 
pathology, which contributes significantly to dementia especially in older patients. One 
would expect that effective hypertension and diabetes management throughout life should 
decrease risk of damage, but the exact association and magnitude of potential protection 
is unknown without large, lengthy longitudinal studies. 
Strengths of this study include multiple measures of AHT exposure, consideration 
of many AHT medications, consideration of multiple pathological outcomes, and 
consideration of causal pathways and adjustment for confounders using a DAG model. 
As mentioned earlier, this study is limited by the quality of exposure measurements, as 
fully measuring lifetime exposure and degree of cardiovascular disease was not possible. 
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The study is also limited by selection bias common to a longitudinal study of this nature, 
as evidenced in the homogeneity of the study sample. 
More work is needed to more fully investigate the potential for AHT to protect 
against cerebrovascular pathology. Ideally, lifelong follow up gathering information 
regarding morbidities, blood pressure, medications, etc. would be combined with autopsy 
data to provide a more comprehensive assessment of how blood pressure control affects 
brain pathology and cognitive impairment. The SPRINT Trial, which tested whether a 
lower-than-currently-recommended systemic blood pressure goal would be beneficial, 
included secondary cognitive endpoints, including incidence of dementia and brain 
volume.30 However, the study was still limited in follow up and was ultimately 
discontinued early. As decades-long randomized controlled trials would be unfeasible, 
more thorough observational studies are the best avenue for future research.  
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TABLES AND FIGURES 
 
Figure 1: Directed Acyclic Diagram (DAG). Relationships of covariates and the 
outcome are shown. Developed using www.dagitty.net. AHT = anti-hypertensive 
treatment; HTN = hypertension; CVD = cardiovascular disease including atrial 
fibrillation, congestive heart failure, stroke, and heart attack; SES = socioeconomic 
status; FH = family history 
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Figure 2: Study inclusion and exclusion.  
 
  
*Sample size varied by outcome analyses   
NACC Uniform Dataset 
(March 2015) 
N = 32,938 
Autopsies 
N = 3,920 (59% of deaths) 
Deaths 
N = 6,656 
Documented Diabetes 
N = 501 (12.8% of autopsies) 
17 participants excluded for missing/unknown 
exposure to AHT (0.4% of autopsies) 
484 participants included*  
(12.3% of autopsies) 
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Table 1: Distribution and bivariate analysis of demographic variables.  
 
 
 
Continuous variables are expressed as mean ± standard deviation. Categorical variables 
are expressed as number and percentage. 
* Statistically significant (p<0.05) 
 
  
Variable 
All 
n = 484 
No AHT 
n = 90 
Any AHT 
n = 394 
P-value 
Age at Death 79.2 ± 9.7 75.5 ± 11.3 80.1 ± 9.2 0.0005* 
Year of Death 2011 ± 2.4 2010.4 ± 2.6 2011.2 ± 2.4 0.0061* 
Male 303 (62.6%) 57 (63.3%) 246 (62.4%) 0.8740 
Caucasian Race 426 (90.1%) 81 (91.0%) 345 (89.8%) 0.8554 
Hispanic Ethnicity 41 (8.5%) 11 (12.2%) 30 (7.7%) 0.1611 
Body Mass Index 27.6 ± 5.9 26.3 ± 5.6 27.8 ± 6.0 0.0836 
Years of Education 14.5 ± 3.7 14.2 ± 3.9 14.6 ± 3.6 0.3525 
Living Alone 57 (11.8%) 6 (6.7%) 51 (12.9%) 0.1014 
Residence Type    0.1506 
Private Residence 313 (66.2%) 54 (60.7%) 259 (67.5%)  
Retirement Community 
or Independent Group 
Living 
32 (6.8%) 5 (5.6%) 27 (7.0%)  
Assisted living, adult 
family home, or 
boarding home 
54 (11.4%) 9 (10.1%) 45 (11.7%)  
Skilled nursing facility, 
nursing home, hospital, 
or hospice 
74 (15.6%) 21 (23.6%) 53 (13.8%)  
Total Visits 3.3 ± 2.0 2.3 ± 1.9 3.5 ± 2.0 <0.0001* 
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Table 2: Distribution and bivariate analysis of past medical history.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Continuous variables are expressed as mean ± standard deviation. Categorical variables 
are expressed as number and percentage. 
* Statistically significant (p<0.05) 
  
Variable 
All 
n = 484 
No AHT 
n = 90 
Any AHT 
n = 394 
P-value 
Hypertension 390 (80.6) 34 (38.6) 356 (90.4) <0.0001* 
Stroke 119 (24.6) 15 (16.7) 104 (26.5) 0.0517 
Atrial Fibrillation 96 (19.8) 4 (4.4) 92 (23.5) <0.0001* 
Myocardial Infarction 84 (17.4) 5 (5.6) 79 (20.1) 0.0010* 
Congestive Heart Failure 65 (13.4) 1 (1.1) 64 (16.4) 0.0001* 
Cardiovascular Disease 234 (48.4) 21 (23.3) 213 (54.1) <0.0001* 
Hypercholesterolemia 352 (72.37 54 (60.7) 298 (76.2) 0.0028* 
Alcohol Abuse 61 (12.6) 6 (6.7) 55 (14.0) 0.0590 
Years of Smoking 12.3 ± 16.6 9.2 ± 14.6 13.1 ± 17.0 0.0349* 
Diabetes Treatment 319 (65.9) 54 (60.7) 265 (68.7) 0.1485 
Dementia 372 (76.9) 82 (91.1) 290 (73.6) 0.0004* 
Alzheimer's Pathology 193 (40.7) 46 (52.3) 147 (38.1) 0.0145* 
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Table 3: Distribution and bivariate analysis of cerebrovascular outcomes.  
 
Results expressed as number and percentage.  
Neuropathology All No AHT Any AHT P-value 
Any Infarcts (n=373) 147 (39.4%) 23 (29.9%) 124 (41.9%) 0.0545 
Large Infarcts (n=373) 52 (13.9%) 6 (7.8%) 46 (15.5%) 0.0804 
Lacunes (n=372) 95 (25.5%) 16 (20.8%) 79 (26.8%) 0.2823 
Microinfarcts (n=372) 70 (18.8%) 14 (18.2%) 56 (19.0%) 0.8727 
Arteriolosclerosis (n=428)    0.4304 
None 72 (16.8%) 16 (19.8%) 56 (16.1%)  
Mild 158 (36.9%) 29 (35.8%) 129 (37.2%)  
Moderate 131 (30.6%) 20 (24.7%) 111 (32.0%)  
Severe 67 (15.7%) 16 (19.8%) 51 (14.7%)  
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Table 4: Unadjusted logistic regression.  
Odds ratios and 95% confidence intervals shown. 
* Statistically significant (p<0.05) 
  
Neuropathology Any AHT Last Visit % of Visits on AHT 
Any Infarct 1.69 (0.99-2.90) 1.64 (1.01-2.67)* 1.72 (1.01-2.94)* 
Large Infarct 2.18 (0.89-5.31) 2.22 (1.01-4.91)* 2.56 (1.07-6.11)* 
Small Infarct 1.39 (0.76-2.56) 1.51 (0.86-2.63) 1.41 (0.77-2.57) 
Microinfarct 1.05 (0.55-2.02) 1.08 (0.6-1.96) 1.13 (0.58-2.17) 
Arteriolosclerosis    
Mild 1.27 (0.64-2.52) 1.44 (0.78-2.66) 1.18 (0.59-2.37) 
Moderate 1.59 (0.76-3.30) 1.52 (0.8-2.87) 1.49 (0.72-3.09) 
Severe 0.91 (0.41-2.01) 1.03 (0.50-2.11) 0.91 (0.4-2.04) 
Table 5: Adjusted logistic regression. 
Model 1 adjusted for HTN and CVD. Model 2 adjusted for HTN, CVD, age at death, and history of hypercholesterolemia. Odds ratios 
and 95% confidence intervals shown. 
* Statistically significant (p<0.05) 
 Any AHT Exposure Last Visit AHT % of Visits on AHT 
Neuropathology Model 1 Model 2 Model 1 Model 2 Model 1 Model 2 
Any Infarct 1.35 (0.71-2.56) 1.05 (0.54-2.05) 1.37 (0.78-2.40) 1.19 (0.67-2.12) 1.39 (0.75-2.61) 1.18 (0.62-2.25) 
Large Infarct 2.60 (0.88-7.67) 2.02 (0.68-6.05) 2.59 (1.02-6.58)* 2.11 (0.83-5.39) 3.15 (1.13-8.78)* 2.72 (0.95-7.76) 
Lacune 1.19 (0.57-2.45) 0.88 (0.42-1.86) 1.37 (0.72-2.60) 1.18 (0.61-2.27) 1.20 (0.59-2.44) 0.97 (0.47-2.02) 
Microinfarct 1.09 (0.50-2.39) 0.89 (0.40-1.97) 1.12 (0.56-2.24) 0.97 (0.48-1.95) 1.19 (0.54-2.59) 1.02 (0.46-2.26) 
Arteriolosclerosis       
Mild 1.24 (0.56-2.76) 1.18 (0.53-2.66) 1.46 (0.74-2.90) 1.43 (0.71-2.86) 1.13 (0.51-2.49) 1.10 (0.50-2.43) 
Moderate 1.43 (0.60-3.43) 1.32 (0.55-3.19) 1.34 (0.65-2.77) 1.31 (0.63-2.72) 1.33 (0.57-3.11) 1.26 (0.54-2.97) 
Severe 0.66 (0.26-1.68) 0.61 (0.24-1.57) 0.85 (0.38-1.90) 0.83 (0.37-1.87) 0.68 (0.27-1.75) 0.64 (0.25-1.65) 
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